Roivant Sciences Ltd.
ROIV
$11.31
-$0.05-0.44%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.57M | 9.02M | 4.48M | 7.99M | 9.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.57M | 9.02M | 4.48M | 7.99M | 9.02M |
| Cost of Revenue | 145.04M | 140.15M | 141.41M | 118.92M | 105.95M |
| Gross Profit | -137.47M | -131.14M | -136.93M | -110.93M | -96.93M |
| SG&A Expenses | 227.69M | 132.35M | 117.18M | 92.99M | 99.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 372.74M | 272.50M | 258.59M | 211.91M | 205.65M |
| Operating Income | -365.17M | -263.48M | -254.11M | -203.92M | -196.63M |
| Income Before Tax | -203.05M | -234.51M | -224.38M | -19.64M | -100.73M |
| Income Tax Expenses | 49.32M | -25.57M | 12.46M | 11.96M | -5.77M |
| Earnings from Continuing Operations | -252.38M | -208.95M | -236.84M | -31.60M | -94.96M |
| Earnings from Discontinued Operations | 0.00 | 327.02M | -43.08M | 89.09M | -87.54M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 45.90M | 51.31M | 49.74M | 37.81M | 31.38M |
| Net Income | -206.48M | 169.38M | -230.18M | 95.30M | -151.12M |
| EBIT | -365.17M | -263.48M | -254.11M | -203.92M | -196.63M |
| EBITDA | -357.00M | -261.54M | -252.13M | -199.04M | -182.84M |
| EPS Basic | -0.29 | 0.23 | -0.31 | 0.13 | -0.19 |
| Normalized Basic EPS | -0.20 | -0.10 | -0.09 | -0.06 | -0.06 |
| EPS Diluted | -0.29 | 0.23 | -0.31 | 0.12 | -0.19 |
| Normalized Diluted EPS | -0.20 | -0.10 | -0.09 | -0.06 | -0.06 |
| Average Basic Shares Outstanding | 707.30M | 722.72M | 735.47M | 735.81M | 802.86M |
| Average Diluted Shares Outstanding | 707.30M | 722.72M | 735.47M | 735.81M | 802.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |